These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15835500)

  • 21. Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.
    McNamee P; Vanoli A; Hutchings D; McKeith I; Bond J
    J Nutr Health Aging; 2010 Oct; 14(8):664-8. PubMed ID: 20922343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valued lives: Britain stirs outcry by weighing benefits of drugs versus price; government arm finds pills for Alzheimer's too costly, angering patients, Pfizer.
    Whalen J
    Wall St J (East Ed); 2005 Nov; ():A1, A11. PubMed ID: 16502534
    [No Abstract]   [Full Text] [Related]  

  • 23. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany.
    Guo S; Hernandez L; Wasiak R; Gaudig M
    J Med Econ; 2010; 13(4):641-54. PubMed ID: 20958114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NICE faces legal challenge over Alzheimer's drug.
    Dyer C
    BMJ; 2007 Mar; 334(7595):654-5. PubMed ID: 17395920
    [No Abstract]   [Full Text] [Related]  

  • 25. NICE approves drugs for Alzheimer's disease.
    Kmietowicz Z
    BMJ; 2001 Jan; 322(7280):190. PubMed ID: 11159606
    [No Abstract]   [Full Text] [Related]  

  • 26. Prescribing. Short rations.
    Benbow S; Jones R; Jolley D
    Health Serv J; 1999 Sep; 109(5672):26-7. PubMed ID: 10558200
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of donepezil therapy on health costs in a Medicare managed care plan.
    Hill JW; Futterman R; Mastey V; Fillit H
    Manag Care Interface; 2002 Mar; 15(3):63-70. PubMed ID: 11925682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea.
    Suh GH
    Value Health; 2009; 12 Suppl 3():S49-54. PubMed ID: 20586982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Relief for caregivers. Anti-dementia drug saves costs].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697297
    [No Abstract]   [Full Text] [Related]  

  • 30. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
    Truter I
    Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Early diagnosis and therapy of Alzheimer dementia. Careful documentation prevents degeneration].
    Kohler J; Riepe MW; Jendroska K; Pilartz H; Adler G; Berger FM; Calabrese P; Frölich L; Gertz HJ; Hampel H; Haupt M; Mielke R; Paulus HJ; Zedlick D
    MMW Fortschr Med; 2002 Nov; 144(47):53-4. PubMed ID: 12532523
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidence of cholinergic and memantine treatment in Alzheimer's disease in Finland.
    Virta L; Viramo P
    J Am Geriatr Soc; 2007 Nov; 55(11):1886-7. PubMed ID: 17979907
    [No Abstract]   [Full Text] [Related]  

  • 33. Alzheimer's disease. Three-score years and then?
    Bryan J
    Health Serv J; 1998 Aug; 108(5619):suppl 4-5, 7-8. PubMed ID: 10185456
    [No Abstract]   [Full Text] [Related]  

  • 34. Alzheimer disease: progress or profit?
    Mount C; Downton C
    Nat Med; 2006 Jul; 12(7):780-4. PubMed ID: 16829947
    [No Abstract]   [Full Text] [Related]  

  • 35. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications.
    Fagnani F; Lafuma A; Pechevis M; Rigaud AS; Traykov L; Seux ML; Forette F
    Dement Geriatr Cogn Disord; 2004; 17(1-2):5-13. PubMed ID: 14560059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence.
    Jarosławski S; Toumi M
    Appl Health Econ Health Policy; 2011 Jul; 9(4):209-15. PubMed ID: 21682349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom?
    O'Brien JT
    Lancet Neurol; 2006 Dec; 5(12):994-6. PubMed ID: 17110274
    [No Abstract]   [Full Text] [Related]  

  • 38. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan.
    Lo TF; Hsieh CR
    J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A NICE fallacy.
    Quigley M
    J Med Ethics; 2007 Aug; 33(8):465-6. PubMed ID: 17664304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.